Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study
Bewersdorf J, Shimony S, Shallis R, Liu Y, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Lindsley R, Chen E, Ramos J, Stein A, DeAngelo D, Neuberg D, Stone R, Ball B, Stahl M. Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study. Blood 2023, 142: 2964. DOI: 10.1182/blood-2023-174285.Peer-Reviewed Original ResearchNPM1 mutant acute myeloid leukemiaIntensive induction chemotherapyAcute myeloid leukemiaComposite complete responseMedian overall survivalOverall survivalComplete responseAllo-SCTPt ageAbnormal cytogeneticsCohort studyMyelodysplastic syndromePolymerase chain reactionClinical trialsMyeloid leukemiaNPM1 mutationsLarge multicenter retrospective cohort studyTime-varying covariatesMulticenter retrospective cohort studyAllogeneic stem cell transplantationPrior myelodysplastic syndromeMulticenter cohort studyRetrospective cohort studyStem cell transplantationPrior chemotherapy exposureIntensive Induction Chemotherapy with or without Gemtuzumab Ozogamicin Among Patients with Core-Binding Factor Acute Myeloid Leukemia
Rojek A, McCormick B, Cwykiel J, Odetola O, Abaza Y, Achar R, Shallis R, Bradshaw D, Standridge M, Kota V, Badar T, Patel A. Intensive Induction Chemotherapy with or without Gemtuzumab Ozogamicin Among Patients with Core-Binding Factor Acute Myeloid Leukemia. Blood 2023, 142: 2889. DOI: 10.1182/blood-2023-177758.Peer-Reviewed Original ResearchRelapse-free survivalAddition of GOFactor acute myeloid leukemiaGemtuzumab ozogamicinIntensive chemotherapyIntensive induction chemotherapyOverall survivalAcute myeloid leukemiaCBF-AMLComplete responseKIT inhibitorsInduction chemotherapyRemission rateProspective studyPolymerase chain reactionMyeloid leukemiaCore binding factor acute myeloid leukemiaAllogeneic stem cell transplantationMulti-center retrospective studyCore-binding factor acute myeloid leukemiaMeasurable residual disease testingAnthracycline-based inductionEuropean LeukemiaNet guidelinesFavorable-risk AMLInduction-related mortalityTreatment Patterns Among Patients with Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia after Intensive Induction Chemotherapy
Rojek A, McCormick B, Cwykiel J, Odetola O, Abaza Y, Achar R, Shallis R, Bradshaw D, Standridge M, Kota V, Badar T, Patel A. Treatment Patterns Among Patients with Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia after Intensive Induction Chemotherapy. Blood 2023, 142: 1484. DOI: 10.1182/blood-2023-185163.Peer-Reviewed Original ResearchCore-binding factor acute myeloid leukemiaFactor acute myeloid leukemiaIntensive induction chemotherapyOutcome of ptsInitial complete remissionLine therapyComplete remissionLong-term outcomesAcute myeloid leukemiaCBF-AMLPolymerase chain reactionR diseaseInduction chemotherapyMedian OSFirst relapseIntensive inductionInitial diagnosisMyeloid leukemiaMolecular testingNext-generation sequencingKIT inhibitorsMulti-center retrospective studyMeasurable residual disease testingAnthracycline-based inductionEuropean LeukemiaNet guidelines